Compare PCYO & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCYO | EMBC |
|---|---|---|
| Founded | 1976 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.5M | 200.5M |
| IPO Year | 1995 | 2021 |
| Metric | PCYO | EMBC |
|---|---|---|
| Price | $10.71 | $3.26 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.50 |
| AVG Volume (30 Days) | 57.1K | ★ 2.4M |
| Earning Date | 04-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 6.88% |
| EPS Growth | 12.50 | ★ 20.90 |
| EPS | 0.23 | ★ 0.67 |
| Revenue | ★ $1,227,787.00 | N/A |
| Revenue This Year | N/A | $1.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $47.52 | ★ $4.94 |
| Revenue Growth | ★ 171.54 | N/A |
| 52 Week Low | $9.65 | $2.77 |
| 52 Week High | $12.44 | $15.55 |
| Indicator | PCYO | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 49.18 | 39.57 |
| Support Level | $10.71 | $3.01 |
| Resistance Level | $10.96 | $3.48 |
| Average True Range (ATR) | 0.34 | 0.18 |
| MACD | 0.03 | 0.14 |
| Stochastic Oscillator | 37.96 | 43.88 |
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in three business segments namely Water and wastewater resource development, Land development, and the Single-Family Rental Segment. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.